Phaseline

Companies › Omikron Italia S.r.l.

Omikron Italia S.r.l.: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Ophthalmology; next expected readout Apr 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Citicoline eye drops 2%
Phosphatidylcholine precursor with neuroprotective properties
PCYT1APhase 3Glaucoma, Open-AngleApr 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05710198Citicoline eye drops 2%Phase 3Glaucoma, Open-AngleOphthalmologyApr 2027

Targets

PCYT1A (1)

Companies with the same targets

–

Companies built like this

Cloudbreak Therapeutics Viridian Therapeutics Aurion Biotech Smilebiotek Zhuhai Beletalent (Zhuhai) Pharmaceutical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.